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Abstract: The bioactive natural product perophoramidine has proved a challenging synthetic target. 
An alternative route to its indolo[2,3-b]quinolone core structure involving a N-chlorosuccinimde-
mediated intramolecular cyclization reaction is reported. Attempts to progress towards the natural 
product are also discussed with an unexpected deep-seated rearrangement of the core structure 
occurring during an attempted iodoetherification reaction. X-ray crystallographic analysis provides 
important analytical confirmation of assigned structures. 
Keywords: perophoramidine; natural product; Claisen rearrangement; indoloquinoline; intramo-
lecular cyclization; X-ray structure 
 
1. Introduction 
Attempts to prepare complex bioactive natural products often test synthetic method-
ology under very challenging circumstances. In addition, unexpected outcomes, in what 
initially look like simple transformations, frequently occur and provide interesting ana-
lytical conundrums. One approach to solving these structural questions is the use of 
small-molecule X-ray crystallography which continues to play an essential role in devel-
oping routes to complex molecules. Through collaborations, such as ours with Professor 
Alexandra Slawin, difficult analytical challenges are frequently solved with apparent 
ease. For anyone who has had the pleasure to work with someone with Professor Slawin’s 
level of expertise, the phrase “Oh of course Alex, now you’ve pointed it out that has to be 
the structure” will probably be familiar! 
The structure of the natural product perophoramidine 1 (Scheme 1) was first re-
ported in 2002 by Ireland [1] although earlier biosynthetic proposals, synthetic and small 
molecule X-ray crystallographic work had sparked interest in closely related alkaloids [2–
10]. To date, a number of elegant total syntheses of perophoramidine 1 have been reported 
[11–16] along with a range of other attempts [17,18]. In addition, in their initial report, 
Ireland et al. reported the dehalogenation of perophoramidine 1 under hydrogenation 
conditions using HCO2NH4 and Pd/C in MeOH. This led to the formation of a compound 
that they named dehaloperophoramidine 2 (Scheme 1) [1]. Additional syntheses of com-
pound 2 have been reported [19–22], with one of these routes to 2 being developed in our 
laboratory [21. As our studies to 2 progressed, investigations into the synthesis of the hal-
ogen-containing 1 were also carried out. 
Here, we report the successful synthesis of the halogen-containing analogue 3 of 
compound 4, which was a key intermediate in our synthesis of 2 (Scheme 1) [21]. Attempts 
to progress forward from 3 towards 1, using an alternative route to that reported by us 
for the synthesis of 2 [21], are also described. In addition, we include the structural assign-
ment of two of the prepared compounds by small-molecule X-ray crystallographic analy-
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sis, bringing to 18 the total number of times this technique has guided this overall program 
of work (for the previous small molecule X-ray crystallographic structures see CCDC 
737646-737648, 1486344, 1478152-4, 1582892-7 and 1811882-4). 
 
Scheme 1. Structures of the natural product perophoramidine 1 and the product prepared by Ire-
land et al. [1] following dehalogenation, dehaloperophoramidine 2. Previous reports [5c] described 
the synthesis of 4 via a NCS-mediated coupling reaction of 5 and subsequent cyclization of 6. 4 
was then converted to 2 [21]. In this work, access to the analogous intermediate 3 was explored 
with two possible routes either via 7 or an intramolecular NCS-mediated cyclization of 9 consid-
ered. An alternative product, compound 8, from a potential cyclization reaction of 7 was possible. 
Chlorination of the aniline ring in 9 was also a potential side reaction. NCS = N-chlorosuccinimide; 
DMP = N,N’-dimethylpiperazine; TCA = trichloroacetic acid. 
2. Results 
2.1. Proposed Route to Halogenated Intermediate 3 
We have previously reported [21] a robust and scalable route to the indolo[2,3-
b]quinoline core structure of 4 using a N-chlorosuccinimide (NCS)-mediated coupling of 
methyl indole-3-carboxylate (5) with N-benzylaniline followed by cyclization of the prod-
uct 6 in refluxing diphenyl ether (Scheme 1) [23]. This reaction sequence proved a suitable 
starting point for the synthesis of dehaloperophoramidine 2 [21]. Whilst this approach 
was relatively straightforward and high yielding in the case of 4, it seemed likely that the 
analogous reaction using substrate 7 with the required halogenation pattern to prepare 
perophoramidine 1 would lead to the formation of regioisomers 3 and 8 (Scheme 1). It was 
envisaged that separation of 3 and 8 would prove challenging as these type of compounds 
exhibit low solubility in organic solvents. 
To avoid this issue, an alternative approach was proposed involving a NCS-mediated 
cyclization reaction of substituted indole 9 to form the N5–C5a bond in 3 after the C11–
C11a bond. This is an intramolecular version of the reaction used to form 6 (Scheme 1). 
NCS-mediated intramolecular cyclization reactions have recently been used to form a C–
N bond at the indole 2-position in the total synthesis of (−)-chaetominine (10) [8] with 
tetrahydro-1H-pyrido[2,3-b]indole (11) being prepared from substituted indole 12 using 
NCS (1.3 equiv.) and Et3N (4 equiv.) in DCM in 52% yield (Scheme 2). One possible chal-
lenge with this approach in our system was competing chlorination in the aniline ring in 
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9 (Scheme 1). Given difficulties in predicting the result of this competition a priori, it was 
decided to investigate this proposed route to 3. 
 
Scheme 2. Reported synthesis of 11 via a NCS-mediated formation of the C–N bond at the indole 
2-position during the preparation of the natural product (–)-chaetominine (10) [24]. 
2.2. Synthesis of Halogenated Intermediate 3 
Whilst several methods are available for the synthesis of 5,7-dichloroindole (13) [24–
28] including electrochemical-mediated cyclization [25] and gold-catalyzed annulation of 
the corresponding 2-alkynylaniline [26], it was decided to use the Bartoli indole synthesis 
[27,28] as multi-gram quantities of 13 were required (Scheme 3). Reaction of 2,4-dichlo-
ronitrobenzene (14) with vinylmagnesium chloride [28] gave indole 13 with key steps in 
the process involving a [3,3]-sigmatropic rearrangement followed by cyclization onto the 
resulting aldehyde to form the 5-membered ring. The yield of this reaction was relatively 
low (48%, in line with the literature precedent [28]); however, the starting materials were 
readily available and the reaction could be carried out to give almost 9 g of 13. Indole 13 
was subsequently converted to aldehyde 15 using a Vilsmeier-Haack reaction [29] and 
Boc protection of the indole nitrogen using di-tert-butyl dicarbonate (Boc2O) in the pres-
ence of 4-dimethylaminopyridine (DMAP) formed 16 in high yield (Scheme 3). 
 
Scheme 3. Synthesis of ketone 20 involving generation of indole 13 using a Bartoli reaction [27,28] 
and a Knochel-type coupling reaction. TPAP = tetrapropylammonium perruthenate; NMO = N-
methylmorpholine N-oxide. 
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Aryl iodide 17 was then synthesized from 18 in 83% yield using a literature procedure 
(Scheme 3) [30]. Having prepared intermediates 16 and 17, a Grignard-mediated coupling 
reaction was attempted. This reaction was based on a method reported by Knochel et al. 
in which aryl rings containing an iodine atom ortho to a nitro group can undergo I-Mg 
exchange when treated with phenylmagnesium chloride [31,32]. The resulting Grignard 
reagent can then react with an electrophile to form a new carbon–carbon bond. Interest-
ingly, more reactive Grignard reagents such as methyl magnesium chloride react with the 
nitro group, leading to complex mixtures of products. The reaction is also reported to be 
unsuccessful when meta- or para-iodonitrobenzenes are used [31,32], leading to the pro-
posal that chelation of the nitro group to the magnesium atom stabilizes the ortho-substi-
tuted Grignard reagent. The treatment of iodide 17 with phenylmagnesium chloride at 
−40 °C for 1 h followed by reaction with aldehyde 16 gave alcohol 19 (racemate, Scheme 
3) in excellent yield, even on a multiple-gram scale. Alcohol 19 was then oxidized to ke-
tone 20 using tetrapropylammonium perruthenate (TPAP, 5 mol%) and co-oxidant N-
methylmorpholine N-oxide (NMO) (Scheme 3) [33]. 
Attempts were made to reduce the nitro group to the corresponding amine and re-
move the Boc protecting group in one step by refluxing 20 in acetic acid and ethanol in 
the presence of iron powder. However, this reaction produced a mixture of the expected 
product 21 and Boc protected 22. A two step protocol using iron in acetic acid and ethanol 
followed by treatment of purified 22 with TFA in DCM gave 21 in an excellent yield over 
the two steps (Scheme 4). The required reductive N-benzylation of 21 proved more chal-
lenging. When 21 was heated with benzaldehyde in refluxing toluene for six hours fol-
lowed by the addition of sodium triacetoxyborohydride (STAB) the required product 9 
was obtained in only moderate yield presumably due to the relatively poor nucleophilic-
ity of the aniline nitrogen in 21 disfavouring initial imine formation. An alternative im-
proved procedure based on the report of Boros et al. [34] was eventually found. This in-
volved the additional use of TFA and so enabled telescoping of the conversion of 22 to 9 
which after optimization of this reaction (a second aliquot of the STAB/TFA solution after 
30 min) enabled the formation of 9 from 22 to 68% with a small quantity of 21 also being 
obtained (Scheme 4). 
 
Scheme 4. Nitro group reduction and reductive amination. 
After carrying out a series of model studies (see Supplementary Material), a NCS-
mediated cyclization of 9 was attempted. The initial conditions used were NCS (2.0 equiv.) 
and DMP (0.56 equiv.) in DCM at room temperature overnight. After stirring for 28 h, it 
was observed that a small amount of precipitate was formed. The precipitate was isolated 
by filtration, washed with DCM and analyzed by 1H NMR in d6-DMSO (Figure S2). The 
NMR and mass spectrometric analysis was consistent with the presence of two com-
pounds with m/z values equal to the required product 3 and a chlorinated analogue of 3 
(assigned structure 23 (Scheme 5 and Figure S3), vide infra). Analysis of the filtrate and 
washings from the reaction indicated that again two main compounds were present, one 
of which was unreacted 9. The second compound was assigned as 24 (Scheme 5), which 
was presumably formed by NCS-mediated chlorination at the aniline 4-position rather 
than at the indole 3-position of 9. The isolation of 24 also led to the proposal that the uni-
dentified chlorinated analogue of 3 present in the precipitate was in fact 23, the cyclized 
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version of 24. To confirm this, a small-scale reaction of 24 with NCS and base was carried 
out, giving 23 (Scheme 5, Figure S3 and Supplementary Material for protocols and analyt-
ical data for 23 and 24). 
 
Scheme 5. Preliminary attempts at NCS-mediated cyclization of 9 using NCS (2.0 equiv.), DMP 
(0.56 equiv.) in DCM at room temperature for 28 h led to formation of a precipitate that contained 
the desired cyclized product 3 and a second product assigned as 23 (Figure S3, see Supplementary 
Material for analytical data for 23 and 24). 23 was independently prepared from an isolated sam-
ple of 24 (NCS (1.0 equiv.), DMP (0.56 equiv.) in DCM at room temperature for 16 h). Significant 
optimization of this reaction was required. 
Optimization of this reaction started with a solvent screen based on literature prece-
dent [23,24,35,36]. The reaction of 9 with NCS (1.0 equiv.) and DMP (0.56 equiv.) was car-
ried out in seven common solvents (DCM, MeOH, acetone, THF, CH3CN, hexane and tol-
uene) and the amount of precipitate isolated and the ratio of 9:24 in the filtrates was de-
termined (Table S1). Acetonitrile was judged as the preferred solvent as the largest 
amount of precipitate was formed (cyclized products, Table S1, Entry 5). As related reac-
tions have been reported using a range of bases [23,35,36–40], it was decided to react 9 
with NCS (1.2 equiv.) in acetonitrile using six different bases (DMP, NaH, Et3N, DMAP, 
DIPEA and pyridine, Table S2). In brief, the use of Et3N gave the highest product yield 
(48%) with only the required 3 being present in the precipitate and starting material 9 
being the dominant product in the filtrate (Table S2, Entry 3). Further optimization of this 
reaction found that when 2.4 equivalents of both NCS and Et3N were used at room tem-
perature for 18 h, 3 could be isolated in 55% yield with 9 (21%) recovered on purification 
by column chromatography of the filtrate (Scheme 6 and Supplementary Material demon-
strating the reproducibility of this reaction up to a 2 g scale). 
2.3. Installation of the First All-Carbon Quaternary Center and X-Ray Structure Determination 
of Advanced Intermediate 27 
After developing the route to ketone 3, the instalment of the first of the all-carbon 
quaternary centers (Schemes 1 and 6) present in perophoramidine 1 was achieved over 3 
steps. Reaction of 3 with POCl3 gave 25 in almost quantitative yield. Substitution of one 
of the chlorines in 25 using sodium allyloxide gave allyl ether 26 (Scheme 6) which under-
went Claisen rearrangement to form ketone 27 on heating at reflux in THF for 12 h. Re-
crystallization of 27 provided crystals suitable for X-ray crystallographic analysis, which 
enabled confirmation of its structure (Figure 1). This three-step sequence was also suc-
cessful when the alkoxide formed from the reaction of racemic 3-buten-2-ol with sodium 
was used. As observed previously in the dehalo system (Scheme S4) [21], the Claisen re-
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arrangement of the crotyl-containing 28 generated from 25 was feasible at room tempera-
ture (unlike allyl-containing 26 which does not rearrange at all at room temperature) and 
as a result it was not possible to isolate 28 in pure form. Heating the obtained sample of 
predominantly 28 at reflux in THF only required 1 h for full conversion to 29 in 75% yield 
over the two steps (c.f. the 12 h at reflux in THF required for complete conversion of 26 to 
27 and the 5 h required in the analogous reaction in the crotyl-dehalo series, Scheme S4). 
It is clear that the presence of the halogens in 28 accelerated the Claisen rearrangement. In 
this sequence it was also interesting to note that the alkoxide addition-elimination reac-
tions of 25 to give 26 or 28 proceeded much faster than the corresponding reaction of 
dehalo analogue which required 18 h to convert fully [23]. This is likely due to the elec-
tron-withdrawing effect of the halogen substituents in 25 promoting nucleophilic addition 
of the alkoxide. Although the synthesis of intermediate 29 was carried out in such a way 
that racemic product was obtained, the use of enantiomerically enriched (R)-3-buten-2-ol 
would enable the formation of the C-10b quaternary center with the correct absolute ste-
reochemistry required for an asymmetric synthesis of perophoramidine 1 [23]. 
 
Scheme 6. Optimized conditions for the conversion of 9 to 3 and instalment of an all-carbon qua-
ternary center in compounds 27 and 29. Insights into the impact of the halogen substituents on 
both the addition-elimination and Claisen rearrangement steps were gained. 
 
Figure 1. A view of the X-ray crystal structure of 27 (ellipsoids drawn at the 50 % probability level) 
used to confirm its structure. 
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2.4. Attempted Progress towards Perophoramidine 1 
The second half of this report briefly describes two approaches that were attempted 
to progress from advanced synthetic intermediates 27 and 29 towards perophoramidine 
1. Whilst ultimately unsuccessful, these approaches did provide additional insights into 
the inherent reactivity of this complex system. One of the initial strategies employed by 
others [17,41] and us [42] for the synthesis of 1 and 2 involved the preparation of a C11-
ester-containing intermediate, in our case, of general structure 30 (Schemes 7 and S5). The 
approach attempted here for installing a C11-ester involved reaction of the previously 
prepared 29 with in situ-generated chloromethyl lithium to form epoxide 31 in good yield 
(Scheme 7). The relative stereochemistry of 31 was tentatively assigned based on the ab-
sence of a nOe correlation between the CH2 of the epoxide and any of the protons of the 
crotyl chain. In addition, the assigned stereochemistry in 31 was expected due to the attack 
of the chloromethyl lithium from the least hindered face of the molecule as was observed 
in previous studies in which proof of structure had been obtained through small-molecule 
X-crystal structure analysis of the analogous dehalo-epoxide [21]. Reductive opening of 
31 to give 32 was then achieved using excess boron trifluoride and sodium cyanoborohy-
dride in moderate yield. It was believed that this reaction proceeded with inversion of 
configuration at the C-11 stereocenter due to hydride attack occurring from the least hin-
dered face, again consistent with previously reported studies in which small-molecule X-
ray analysis of a related dehalo-analogue had been achieved [42]. Unfortunately, the re-
sults obtained from the Jones oxidation [43] of 32 were different to those of the previously 
reported non-halogenated alcohols [42]. Following the reaction by LC–MS showed that 
after just 5 min reaction time, 32 was almost completely consumed with a number of dif-
ferent product peaks being observed in the LC–MS spectrum. From the complex mixture 
of products obtained at this time point, evidence for the presence of 33 was obtained. After 
an increased reaction time (5 h), the initially complex mixture simplified with the major 
product being assigned as the decomposition product 34 (Scheme 7 and Figure S4, ob-
served m/z = 501.17 [M+H]+; theoretical m/z for formation of 34, C23H1381Br35Cl2N2O2 
[M+H]+ 500.96). No evidence for the presence of 33 in the reaction mixture at the 5 h time 
point was found. 
 
Scheme 7. Attempted formation of ester 30 (R = Cl, R1 = Me, R2 = Br) to enable ester alkylation as a 
method of incorporating the second all-carbon quaternary center. Reaction of 32 under Jones oxi-
dation conditions gave 34 rather than the desired 33. 
As conversion of 32 to 34 clearly involved loss of the crotyl group (for one possible 
mechanism see Scheme S6), it was next decided to develop the crotyl chain in 29 (or in fact 
the allyl chain in 27, Scheme 8) by reacting the double bond. Building on an approach 
previously reported by us in the dehalo series [44], 35 became the new target molecule. 
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Subsequent conversion of 35 to 36 could provide an approach to perophoramidine 1 by 
differentiating between the two allyl groups as seen in a related system [21]. 
 
Scheme 8. A. One possible approach to perophoramidine 1 via diallyl-containing compound 35. 
Differentiation between the two allyl groups in 35 could potentially be achieved through an io-
doetherification protocol. B. Synthesis of cyclic ether 41, a precursor to 35. PPTS = pyridinium p-
toluenesulfonate, TsCl = p-toluenesulfonyl chloride. 
After dihydroxylation of the allyl group in 27, the corresponding diastereomeric ac-
etonides 37a/37b (1:1 mixture) were formed in 65% yield over the two steps. Reaction of 
37a/37b with allylmagnesium chloride proceeded in high yield to give only two of the 
possible diastereomers (assigned structures as shown in 38a/38b based on expected stere-
ochemical outcome of addition to the ketone). Deprotection of the acetonide group in 
38a/38b was achieved under relatively mild conditions using PPTS in methanol [45] and 
the resulting crude reaction mixture was treated with lead tetraacetate, leading to lactols 
39a/39b still as a 1:1 mixture of diastereomers. Reduction of 39a/39b with sodium borohy-
dride in methanol gave 40 which could be converted to cyclic ether 41 in excellent yield 
over the two steps. Importantly, after dealing with a series of diastereomeric mixtures for 
several steps in this sequence, recrystallization of 41 by slow evaporation of a solution of 
41 in ethyl acetate provided crystals suitable for small-molecule X-ray crystallography. 
From the data obtained, it was clear that the stereochemistry at the two stereogenic centers 
in 41 was as planned. This places the ether ring almost perpendicular to the tetracyclic 
core of 41, with the allyl substituent on the opposite face to the ether ring (Figure 2). 
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Figure 2. Two views of the X-ray crystal structure of 41 (ellipsoids drawn at the 50 % probability 
level) used to confirm its structure. 
Opening of the cyclic ether in 41 proceeded smoothly with 35 being obtained in 79% 
yield after reaction with TiCl4 and allyltrimethylsilane in DCM at −78 °C for 4.5 h. The 
presence of the halogen substituents in 35 had little effect on this robust reaction which 
has previously been reported to proceed in a similar manner with the non-halogenated 
analogue 42 to give 43 (87% yield[44]). Previous attempts to differentiate between the two 
allyl groups present in 43 using an iodoetherification reaction resulted in the formation of 
44, the structural assignment of which (especially the relative stereochemistry) relied 
heavily on X-ray crystallographic analysis [44]. It was proposed that the presence of the 
chlorine substitutents in 35 may steer the outcome of this reaction away from that ob-
served with 43 as a reduction in the electron density in the aryl ring due to the presence 
of the net deactivating chlorines would be expected to slow the proposed reaction of this 
ring with an intermediate iodonium ion central to the formation of 44 from 43 (Schemes 9 
and S7). 
Reaction of 35 with excess NIS in freshly base-washed CDCl3 was followed by puri-
fication of the crude reaction mixture by column chromatography using triethylamine 
treated silica. Mass spectrometric analysis of the product indicated that one iodine atom 
had been added to the molecule, possibly consistent with the desired formation of 36. 
However, detailed NMR analysis indicated that the structure of the major product from 
this reaction was not the planned iodoether 36 or an analogue of 44. The characterization 
data obtained suggested that a major rearrangement of the molecule had taken place, lead-
ing to the formation of 45 (Schemes 9, S8–S10 and Figure S5 for a more detailed discussion 
of the data used in this assignment). In this case, it was not possible for us to prepare 
suitable quality crystals of 45, emphasizing again how, in the absence of X-ray crystallo-
graphic analysis, certainty in structural assignment and especially stereochemistry can 
prove difficult in such complex systems (compound 45 is a single diastereomer but at pre-
sent the relative stereochemistry at the centers marked * is unknown). 




Scheme 9. Attempted conversion of 35 to 36 led instead to formation of 45. 
3. Experimental 
3.1. General Experimental Details 
Nuclear magnetic resonance (NMR) spectra were recorded on a Bruker Advance 300 
(1H, 300; 13C, 75 MHz), Bruker Advance II 400 (1H, 400; 13C, 101 MHz) or Bruker Ascend 
500 (1H 500; 13C 126 MHz). 13C NMR spectra were recorded using the PENDANT pulse 
sequence. Peaks were assigned where possible with the aid of the two-dimensional NMR 
spectroscopic techniques COSY, HSQC, and HMBC. All NMR spectra were acquired us-
ing the deuterated solvent as the lock and the residual solvent as the internal reference. 
Melting points were recorded in open capillaries using an Electrothermal 9100 melting 
point apparatus. Values are quoted to the nearest 1 °C and are uncorrected. Infrared spec-
tra were recorded on a Perkin Elmer Paragon 1000 FT spectrometer. Absorption maxima 
are reported in wavenumbers (cm−1). Mass spectra were recorded using either atmos-
pheric pressure chemical ionization (APCI) or electrospray (ES) ionization methods in the 
positive or negative ionization mode by Mrs Caroline Horsburgh in the University of St 
Andrews School of Chemistry mass spectrometry service or via the EPSRC Mass Spec-
trometry Service Centre (Swansea, UK). 
3.2. X-Ray Structure Determination for 27 and 41 
X-ray diffraction data for compounds 27 and 41 were collected at 93 K using a Rigaku 
MM007 High Brilliance RA generator/confocal optics and Mercury70 CCD system [Mo 
Kα radiation (λ = 0.71073 Å)]. Intensity data were collected using both ω and φ steps ac-
cumulating area detector images spanning at least a hemisphere of reciprocal space. Data 
for all compounds analyzed were collected and processed (including correction for Lo-
rentz, polarization and absorption) using CrystalClear [46]. Structures were solved by Pat-
terson methods (PATTY [47]) and refined by full-matrix least-squares against F2 
(SHELXL-2018/3 [48]). Non-hydrogen atoms were refined anisotropically, and hydrogen 
atoms were refined using a riding model. All calculations were performed using the Crys-
talStructure [49] interface. Selected crystallographic data are presented in Table S3. Dep-
osition numbers 2109434 and 2109435 contain the supplementary crystallographic data 
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for this paper. These data are provided free of charge by the joint Cambridge Crystallo-
graphic Data Center and Fachinformationszentrum Karlsruhe Access Structures service 
www.ccdc.cam.ac.uk/structures. 
3.3. Preparation of Selected Compounds 
3.3.1. N-Boc-5,7-dichloroindole-3-carbaldehyde 16 
To a suspension of 15 (5.00 g, 23.36 mmol) and Boc2O (5.61 g, 25.69 mmol) in DCM 
(100 mL) was added DMAP (0.342 g, 2.80 mmol). After stirring for 15 min, a saturated 
solution of NaHCO3 (aq.) (100 mL) was added and the reaction mixture extracted with 
DCM (2 × 50 mL). The organic phase was washed with 0.5 M HCl (aq.) (100 mL) before 
being dried (MgSO4), filtered and the solvent removed under reduced pressure to give 16 
as a pale yellow solid that required no further purification (6.93 g, 94%). m.p. 102–103 °C; 
I.R. (KBr) νmax 2924, 1723, 1601, 1465, 1453, 1253, 735 cm-1; 1H NMR (400 MHz, CDCl3) δ 
10.07 (s, 1H, CHO), 8.30 (d, J = 2.0 Hz, 1H, C4-H), 8.20 (s, 1H, C2-H), 7.46 (d, J = 2.0 Hz, 1H, 
C6-H), 1.71 (s, 9H, (CH3)3); 13C NMR (100 MHz, CDCl3) 184.8 (CHO), 147.5 (CO2tBu), 140.0 
(C2), 131.3 (C7a), 130.9 (C3a), 129.9 (C5), 128.0 (C6), 120.7 (C7), 120.6 (C4), 120.2 (C3), 86.9 




To a solution of 17 (5.16 g, 15.70 mmol) in THF (23 mL) at −40 °C was added 2 M 
solution of phenylmagnesium chloride in THF (8.40 mL, 16.80 mmol), followed 15 min 
later by a solution of 16 (3.30 g, 10.50 mmol) in THF (23 mL). The mixture was stirred for 
1 h at −40 °C before being allowed to warm to room temperature for a further 1 h. A satu-
rated solution of NH4Cl (aq.) (50 mL) was then added followed by water (75 mL) and ethyl 
acetate (75 mL). The mixture was separated and the organic phase washed with a satu-
rated solution of NaCl (aq.) (50 mL), dried (MgSO4) and the solvent removed under re-
duced pressure. The crude product was purified by column chromatography (10–20% 
EtOAc/hexanes), giving 19 as a yellow solid (5.21 g, 96%). m.p. 56–58 °C; I.R. (KBr) νmax 
3386, 1737, 1531, 1346, 1150 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.08 (d, J = 2.0 Hz, 1H, C3′-
H), 7.70 (dd, J = 8.4, 2.0 Hz, 1H, C5′-H), 7.57 (d, J = 8.4 Hz, 1H, C6′-H), 7.30 (s, 1H, C2-H), 
7.29 (d, J = 1.9 Hz, 1H, ArC-H), 7.26 (d, J = 1.9 Hz, 1H, ArC-H), 6.50 (d, J = 4.4 Hz, 1H, 
CHOH), 2.84 (d, J = 4.4 Hz, 1H, OH), 1.56 (s, 9H, (CH3)3); 13C NMR (100 MHz, CDCl3) δ 
148.5 (CO2tBu), 148.3 (C2′), 136.8 (C5′), 135.8 (C1′), 132.2 (ArC), 131.3 (ArC), 130.6 (C6′), 
129.0 (ArC), 128.8 (C2), 128.0 (C3′), 126.8 (ArC), 122.4 (C4′), 121.2 (ArC), 119.9 (ArC), 118.1 
(ArC), 85.5 (C(CH3)3), 65.0 (CHOH), 27.8 (C(CH3)3); HR MS [APCI+]: m/z calcd. for 
C20H1779Br35Cl2N2O5NH4 532.0036, found 532.0034 [M+NH4]+. 
3.3.3. tert-Butyl 3-(4-bromo-2-nitrobenzoyl)-5,7-dichloro-1H-indole-1-carboxylate 20 
To a solution of 19 (3.25 g, 6.30 mmol) and N-methylmorpholine-N-oxide (1.48 g, 
12.60 mmol) in DCM (35 mL) in the presence of 3Å molecular sieves at 0 °C was added 
tetrapropylammonium perruthenate (0.110 g, 0.310 mmol). The mixture was stirred for 30 
min at 0 °C followed by a further 6 h at room temperature before the mixture was filtered 
and the solvent removed under reduced pressure. The crude product was purified by col-
umn chromatography (5–25% EtOAc/hexanes), giving 20 as a white solid (2.31 g, 71%). 
m.p. 126-127 °C; I.R. (KBr) νmax 2924, 1745, 1654, 1544, 1348 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 8.42 (d, J = 1.9 Hz, 1H, C4-H), 8.39 (d, J = 1.8 Hz, 1H, C3′-H), 7.95 (dd, J = 8.1, 1.9 
Hz, 1H, C5′-H), 7.64 (s, 1H, C2-H), 7.48 (d, J = 2 Hz, 1H, C6-H), 7.47 (d, J = 8.1 Hz, 1H, C6′-
H), 1.66 (s, 9H, C(CH3)3); 13C NMR (100 MHz, CDCl3) δ 186.2 (C=O), 147.9 (CO2tBu), 147.3 
(C2′), 137.5 (C2), 137.0 (C5′), 134.5 (C1′), 131.1 (C7a), 131.1 (ArC), 130.9 (ArC), 130.0 (C6′), 
128.0 (C6), 128.0 (C3′), 124.5 (C4′), 121.1 (C4), 120.7 (ArC), 118.6 (C3a), 87.5 (C(CH3)3), 27.7 
(C(CH3)3); HR MS [ES+]: m/z calcd. for C20H1579Br35Cl2N2O5 534.9439, found 534.9432 
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[M+H]+.This was prepared as in 3.3.1. using benzotriazole (14.69 g, 123.3 mmol), thionyl 
chloride (3.67 g, 2.24 mL, 30.8 mmol) and (E)-3-(2-methylphenyl)prop-2-enoic acid (5.00 
g, 30.8 mmol). Drying and evaporation followed by recrystallization of the residue 
(CH2Cl2) gave 33 (1.77 g, 22%) as a white powder, m.p. 124–125 °C (Lit. [21] 127–129 °C); 
H 8.47 (1 H, d, J 15, COCH=CH), 8.42 (1 H, dt, J 8, 1, H-4 or 7 of Bt), 8.16 (1 H, dt, J 8, 1, H-
4 or 7 of Bt), 8.07 (1 H, d, J 15, COCH=CH), 7.86 (1 H, d, J 8), 7.69 (1 H, ddd, J 8, 7, 1, H-5 or 
6 of Bt), 7.54 (1 H, ddd, J 8, 7, 1, H-5 or 6 of Bt), 7.40–7.27 (3 H, m) and 2.56 (3 H, s, Me). 
3.3.4. (2-Amino-4-bromophenyl)(5,7-dichloro-1H-indol-3-yl)methanone 21 
To a solution of 22 (800 mg, 1.85 mmol) in DCM (9 mL) was added trifluoroacetic 
acid (3 mL) and the solution was stirred at room temperature for 18 h. The solvent was 
removed under reduced pressure before a saturated solution of NaHCO3 (aq.) (20 mL) 
was added and the mixture extracted with DCM (3 × 20 mL). The organic extracts were 
dried (MgSO4), filtered and the solvent removed under reduced pressure to give 21 as an 
orange solid (673 mg, 94%) that required no further purification. m.p. 191–193 °C; I.R. 
(KBr) νmax 3446, 3346, 1691, 1597, 1428, 1189 cm−1; 1H NMR (400 MHz, d6-DMSO) δ 12.65 
(s, 1H, NH), 8.09 (d, J = 1.9 Hz, 1H, C4-H), 7.94 (d, J = 3.1 Hz, 1H, C2-H), 7.53 (d, J = 8.4 Hz, 
1H, C6′-H), 7.46 (d, J = 1.8 Hz, 1H, C6-H), 7.03 (d, J = 1.9 Hz, 1H, C3′-H), 6.73 (dd, J = 8.4, 
1.9 Hz, 1H, C5′-H), 6.64 (br. s, 2H, NH2); 13C NMR (100 MHz, d6-DMSO) δ 190.3 (C=O), 
151.0 (C2′), 136.0 (C2), 133.5 (C6′), 132.6 (C7a), 129.2 (C3a), 126.7 (C5), 126.6 (C3), 126.3 
(C4′), 122.2 (C6), 119.6 (C4), 119.1 (C1′), 118.5 (C3′), 117.6 (C5′) 116.8 (C7); HR MS (ES-) m/z 
calcd. for C15H879Br35Cl2N2O 380.9197, found 380.9192 [M-H]−. 
3.3.5. tert-Butyl 3-(2-amino-4-bromobenzoyl)-5,7-dichloro-1H-indole-1-carboxylate 22 
A suspension of 20 (1.00 g, 1.945 mmol) and iron powder (0.543 g, 9.725 mmol) in 
acetic acid (10 mL) and ethanol (10 mL) was stirred for 18 h at room temperature. The 
mixture was filtered through a plug of Celite. The celite was washed with DCM (50 mL) 
and combined with the existing filtrate. Water (50 mL) was added. The mixture was par-
titioned and the aqueous layer further extracted with DCM (2 × 25 mL). The combined 
organic layers were concentrated under reduced pressure before being re-dissolved in 
DCM (50 mL), washed with a saturated solution of NaHCO3 (aq.) (100 mL), dried 
(MgSO4), filtered and the solvent removed under reduced pressure. The crude product 
was purified by column chromatography (10–25% EtOAc/hexanes) to give 22 as a yellow 
solid (0.876 g, 93%). m.p. 143–144 °C; I.R. (KBr) νmax 3442, 3336, 1735, 1645, 1605 cm−1; 1H 
NMR (400 MHz, d6-DMSO) δ 8.01 (d, J = 2.0 Hz, 1H, C4-H), 7.80 (s, 1H, C2-H), 7.44 (d, J = 
8.5 Hz, 1H, C6′-H), 7.35 (d, J = 1.9 Hz, 1H, C6-H), 6.87 (d, J = 1.8 Hz, 1H, C3′-H), 6.75 (dd, 
J = 8.4, 1.9 Hz, 1H, C5′-H), 5.87 (br. s, 2H, NH2), 1.58 (s, 9H, C(CH3)3); 13C NMR (100 MHz, 
d6-DMSO) δ 190.8 (C=O), 150.9 (C2′), 147.0 (CO2tBu), 135.7 (C2), 133.7 (C6′), 132.4 (C7a), 
130.3 (C), 130.0 (C), 128.9 (C4′), 127.4 (C6), 120.8 (C), 120.6 (C4), 119.5 (C3′), 119.3 (C5′), 
119.3 (C), 118.6 (C1′), 86.6 (C(CH3)3), 27.8 (C(CH3)3); HR MS [ES+]: m/z calcd. for 
C20H1779Br35Cl2N2O3Na 504.9697, found 504.9693 [M+Na]+. 
3.3.6. (2-Benzylamino)-4-bromophenyl)(5,7-dichloro-1H-indol-3-yl)methanone 9 
To a solution of 22 (1.00 g, 2.07 mmol) in TFA (8 mL) was added sodium triacetoxy-
borohydride (0.875 g, 4.13 mmol). After 5 min, a solution of benzaldehyde (0.219 g, 2.07 
mmol) in DCM (8 mL) was added dropwise and the solution was stirred for 1 h at room 
temperature. A second aliquot of sodium triacetoxyborohydride (0.875 g, 4.13 mmol) in 
TFA (4mL) was added and the mixture was stirred for a further 1 h at room temperature. 
The mixture was then poured into an ice cold saturated solution of NaHCO3 (aq.) (20 mL) 
and extracted with DCM (3 × 10 mL). The combined organic extracts were dried (MgSO4), 
filtered and the solvent removed under reduced pressure before the crude product was 
purified by column chromatography (5-30% EtOAc/hexanes), giving 22 as an orange-yel-
low solid (0.558 g, 68%). m.p. 81–82 °C; I.R. (KBr) νmax 1691 (C=O), 1602, 1419, 1185 cm−1; 
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1H NMR (400 MHz, CDCl3) δ 8.81 (br. s, 1H, NH), 8.28 (br. t, J = 5.3 Hz, 1H, NHBn), 8.05 
(d, J = 1.5 Hz, 1H, C4-H), 7.54 (d, J = 2.9 Hz, 1H, C2-H), 7.48 (d, J = 8.4 Hz, 1H, C6′-H), 7.30–
7.19 (m, 6H, C6-H and 5 x ArC-H), 6.83 (d, J = 1.8 Hz, 1H, C3′-H), 6.68 (dd, J = 8.4, 1.9 Hz, 
1H, C5′-H), 4.34 (d, J = 5.5 Hz, 2H, CH2); 13C NMR (100 MHz, CDCl3) δ 191.6 (C=O), 151.0 
(C2′), 137.9 (ArC), 134.1 (C6′), 132.6 (C2), 132.1 (C7a), 129.2 (C4′), 128.8 (ArCH), 128.4 (C3a), 
128.3 (C3), 127.5 (ArCH), 127.3 (ArCH), 123.5 (C6), 120.5 (C4), 118.9 (ArC), 118.5 (C1′), 
117.8 (C5′), 117.3 (C), 114.7 (C3′), 47.2 (CH2); HR MS [ES-]: m/z calcd. for C22H1479Br35Cl2N2O 
470.9667, found 470.9673 [M-H]−. 21 was also obtained as an orange solid (0.151 g, 19%). 
3.3.7. 5-Benzyl-3-bromo-7,9-dichloro-5H-indolo[2,3-b]quinolin-11(6H)-one 3 
To a solution of 9 (250 mg, 0.527 mmol) in MeCN (6 mL) was added N-chlorosuccin-
imide (169 mg, 1.265 mmol) and Et3N (176 μL, 1.265 mmol). The mixture was stirred for 
24 h at room temperature before the precipitate was collected by filtration, giving 3 as a 
cream-colored solid (137 mg, 55%). m.p. >320 °C (dec.); I.R. (KBr) νmax 1706, 1603, 1536, 
1181 cm−1; 1H NMR (400 MHz, d6-DMSO) δ 12.45 (br. s, 1H, NH), 8.27 (d, J = 8.5 Hz, 1H, 
C1-H), 8.14 (d, J = 1.9 Hz, 1H, C10-H), 7.78 (d, J = 1.6 Hz, 1H, C4-H), 7.54 (dd, J = 8.5, 1.6 
Hz, 1H, C2-H), 7.46 (d, J = 1.9 Hz, 1H, C8-H), 7.36–7.26 (m, 3H, 3 x ArC-H), 7.18–7.16 (m, 
2H, 2 × ArC-H), 5.98 (s, 2H, CH2); 13C NMR (100 MHz, d6-DMSO) δ 171.4 (C=O), 148.0 
(C5a), 139.6 (C4a), 135.6 (ArC), 130.6 (C6a), 129.0 (ArCH), 127.9 (C1), 127.5 (ArCH), 126.5 
(ArC), 126.3 (ArC), 126.0 (ArCH), 125.6 (C2), 125.5 (C3), 123.8 (C11a), 122.4 (C8), 118.8 (C4), 
118.0 (C10), 116.2 (ArC), 49.0 (CH2); HR MS [ES+]: m/z calcd. for C22H1435Cl281BrN2O 
470.9661, found 470.9659 [M+H]+. 
3.3.8. 5-Benzyl-3-bromo-7,9,11-trichloro-5H-indolo[2,3-b]quinoline 25 
A solution of 3 (1.50 g, 3.18 mmol) in POCl3 (15 mL) was heated to reflux for 1 h before 
removing the solvent under reduced pressure. DCM (100 mL) and a saturated solution of 
NaHCO3 (aq.) (250 mL) were added and the mixture partitioned before the organic layer 
was dried (MgSO4), filtered and concentrated to give 25 in sufficient purity without fur-
ther purification (1.54 g, 99%). m.p. 260–263 °C; I.R. (KBr) νmax 1705, 1602, 1484, 1175, 847 
cm-1; 1H NMR (400 MHz, CDCl3) δ 8.31 (d, J = 2.0 Hz, 1H, C10-H), 8.28 (d, J = 8.8 Hz, 1H, 
C1-H), 7.87 (d, J = 1.7 Hz, 1H, C4-H), 7.59 (d, J = 1.7 Hz, 1H, C2-H), 7.58 (d, J = 2.0 Hz, 1H, 
C8-H), 7.36–7.27 (m, 5H, 5 × Ar-H), 6.20 (s, 2H, CH2); 13C NMR (101 MHz, CDCl3) δ 155.4 
(C5a), 150.3 (C6a), 137.2 (ArC), 134.8 (ArC), 129.3 (C8), 129.1 (ArCH), 128.1 (ArCH), 127.7 
(C1), 127.0 (ArCH), 126.9 (ArC), 126.3 (C2), 125.9 (ArC), 125.6 (ArC), 124.4 (ArC), 123.2 
(ArC), 122.0 (C10), 118.5 (C4), 118.3 (ArC), 50.0 (CH2); HR MS (ES+) m/z calcd. for 
C22H12N235Cl381BrNa 512.9127, found 512.9130 [M+Na]+. 
3.3.9. 11-(Allyloxy)-5-benzyl-3-bromo-7,9-dichloro-5H-indolo[2,3-b]quinoline 26 
To a suspension of sodium (77 mg, 3.36 mmol) in THF (2 mL) at room temperature 
was added allyl alcohol (0.76 mL, 11.21 mmol) dropwise to maintain a steady reaction. 
Once all of the sodium had dissolved, the alkoxide solution was added via cannula to a 
stirred solution of 25 (550 mg, 1.12 mmol) in THF (11 mL) and the mixture was stirred at 
room temperature for 2 h. A saturated solution of NH4Cl (aq.) (10 mL) was added. The 
solvent was removed under reduced pressure and the crude residue was extracted with 
DCM (3 × 30 mL). The combined organic extracts were dried (MgSO4) filtered and concen-
trated under reduced pressure, giving 26 in sufficient purity without any further purifi-
cation as an orange solid (525 mg, 91%). m.p. 225–227 °C; I.R. (KBr) νmax 2925, 1641, 1561, 
1487, 1177, 858 cm−1; 1H NMR (300 MHz, CDCl3) δ 8.18 (d, J = 8.7 Hz, 1H, Ar-H), 7.99 (d, J 
= 2.0 Hz, 1H, Ar-H), 7.86 (d, J = 1.6 Hz, 1H, Ar-H), 7.56 (d, J = 1.9 Hz, 1H, Ar-H), 7.53 (dd, 
J = 8.7, 1.7 Hz, 1H, Ar-H), 7.37–7.27 (m, 5H, 5 × Ar-H), 6.32–6.20 (m, 1H, CH2=CH), 6.19 (s, 
2H, CH2N), 5.56 (dq, J = 17.1, 1.4 Hz, 1H, CH2=CH), 5.43 (dq, J = 10.4, 1.1 Hz, 1H, CH2=CH), 
4.99 (dt, J = 5.7, 1.3 Hz, 2H, CH2); 13C NMR (75 MHz, CDCl3) δ 158.7 (C5a), 158.4 (C11), 
149.4 (ArC), 148.9 (ArC), 138.6 (C4a), 135.2 (ArC), 132.0 (CH=CH2), 129.1 (ArCH), 128.0 
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(ArCH), 127.9 (ArCH), 127.0 (ArCH), 126.5 (C), 126.1 (ArCH), 125.6 (ArCH), 125.2 (ArC), 
124.7 (ArC), 121.3 (ArCH), 119.8 (CH=CH2), 118.5 (ArCH), 117.0 (ArC), 116.0 (ArC), 76.1 




A solution of 26 (500 mg, 0.98 mmol) in toluene (10 mL) was heated to reflux for 1.5 
h before removing the solvent under reduced pressure. The crude product was purified 
by column chromatography (10–25 % EtOAc/hexanes) to give 27 as an orange-yellow solid 
(477 mg, 95%). Recrystallization by slow evaporation of a solution of 27 in EtOAc/Hexane 
provided crystals suitable for X-ray analysis. m.p. 240 °C (dec.); I.R. νmax 1695, 1543, 1196, 
854 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.80 (d, J = 8.8 Hz, 1H, C1-H), 7.59 (d, J = 2.0 Hz, 
1H, C10-H), 7.43–7.37 (m, 5H, 5 × ArC-H), 7.33 (m, 1H, ArC-H), 7.29–7.26 (m, 2H, 2 × ArC-
H), 5.98 (d, J = 16.4 Hz, 1H, 1 × CH2N), 5.38 (ddt, J = 16.9, 10.1, 7.3 Hz, 1H, CH=CH2), 5.14–
5.03 (m, 2H, 1 × CH2N, 1 × CH=CH2), 4.90 (dd, J = 16.8, 1.3 Hz, 1H, CH=CH2), 2.87 (dd, J = 
13.4, 6.9 Hz, 1H, CH2), 2.53 (dd, J = 13.4, 7.7 Hz, 1H, CH2); 13C NMR (101 MHz, CDCl3) δ 
190.4 (C11), 172.2 (C5a), 149.0 (C6a), 145.1 (C4a), 135.7 (C10a), 135.4 (C), 131.1 (C3), 129.7 
(C1), 129.2 (ArCH), 129.1 (ArCH), 129.1 (ArC), 128.9 (C10bII), 128.0 (ArCH), 126.8 (ArCH), 
126.4 (ArCH), 123.9 (ArC), 123.5 (C10), 121.6 (C10bIII), 118.9 (ArCH), 117.6 (ArC), 67.0 
(C10b), 49.9 (C10bI), 44.8 (CH2N); HR MS (ES+) m/z calcd. for C25H1779Br35Cl37ClN2ONa 
534.9769, found 534.9767 [M+Na]+. 
3.3.11. (E)-5-Benzyl-3-bromo-10b-(but-2-en-1-yl)-7,9-dichloro-5H-indolo[2,3-b]quinolin-
11(10bH)-one 29 
To a suspension of sodium (205 mg, 8.93 mmol) in THF (5 mL) at room temperature 
was added (±)-3-buten-2-ol (2.58 mL, 29.76 mmol) dropwise to maintain a steady reaction. 
Once all of the sodium had dissolved, the alkoxide solution was added via a cannula to a 
stirred solution of 25 (1.46 g, 2.98 mmol) in THF (30 mL) and the mixture was stirred at 
room temperature for 2 h. A saturated solution of NH4Cl (aq.) (30 mL) was added before 
the organic solvent was removed under reduced pressure and the crude residue extracted 
with DCM (3 × 100 mL). The combined organic extracts were dried (MgSO4), filtered and 
concentrated under reduced pressure to give a crude product that contained 28 and 29. 
This residue was redissolved in THF (30 mL) and the solution was heated at reflux for 1 h 
before removing the solvent under reduced pressure to give the crude product. Purifica-
tion by column chromatography (10–25% EtOAc/hexanes) gave 29 as a yellow solid (1.17 
g, 75%). m.p. 140–142 °C; νmax 1698, 1590, 1545, 1196, 855 cm−1; 1H NMR (500 MHz, CDCl3) 
δ 7.71 (d, J = 8.6 Hz, 1H, C1-H), 7.48 (d, J = 2.0 Hz, 1H, C10-H), 7.36–7.14 (m, 8H, 8 × ArC-
H), 5.91 (d, J = 16.3 Hz, 1H, CH2N), 5.21 (dq, J = 12.6, 5.8 Hz, 1H, C10bII-H), 5.01–4.88 (m, 
2H, CH2N + C10bIII-H), 2.74 (dd, J = 13.2, 6.4 Hz, 1H, C10bI-H2), 2.35 (dd, J = 13.2, 8.1 Hz, 
1H, C10bI-H2), 1.49 (d, J = 6.2 Hz, 3H, C10bIV-H3); 13C NMR (126 MHz, CDCl3) δ 190.5 (C11), 
172.4 (C5a), 148.9 (C6a), 145.1 (C4a), 136.0 (C10a), 135.5 (C), 132.9 (C10bII), 131.0 (C3), 129.6 
(C1), 129.1 (ArCH), 129.0 (ArCH), 128.9 (ArC), 128.0 (ArCH), 126.8 (ArCH), 126.3 (ArCH), 
123.8 (ArC), 123.6 (C10), 121.4 (C10bIII), 118.8 (C8), 117.8 (C11a), 67.4 (C10b), 49.9 (CH2N), 
44.3 (C10bI), 17.9 (C10bIV); HR MS (ES-) m/z calcd. for C26H18N2O35Cl281Br 524.9959, found 
524.9971 [M − H]−. 
3.3.12. 5-Benzy-3-bromo-10b-((E)-but-2-en-1-yl)-7,9-dichloro-5,10b-
dihydrospiro[indolo[2,3-b]quinoline-11,2′-oxirane] 31 
To a solution of 29 (200 mg, 0.380 mmol) and chloroiodomethane (42 μL, 0.570 mmol) 
in THF (4 mL) at −78 °C was added methyl lithium—lithium bromide complex (1.5 M in 
THF, 0.38 mL, 0.570 mmol) dropwise over 5 min. The mixture was stirred at −78 °C for a 
Molecules 2021, 26, 6039 15 of 19 
 
 
further 30 min before removing the cold bath and stirring for a further 18 h at room tem-
perature. A solution of saturated NH4Cl (aq.) (10 mL) was added and the mixture ex-
tracted with DCM (3 × 10 mL) before the combined organic extracts were dried (MgSO4), 
filtered and concentrated. The crude product was purified by column chromatography 
(10–20 % EtOAc/hexanes) to give 31 as an orange solid (142 mg, 74%). m.p. 90–93 °C; I.R. 
(KBr) νmax 2921, 1709, 1595, 1550, 1486, 729 cm−1; 1H NMR (400 MHz, CDCl3) δ 7.41–7.35 
(m, 4H, 4 × ArC-H), 7.33–7.28 (m, 2H, 2 × ArC-H), 7.19 (dd, J = 8.1, 1.7 Hz, 1H, C2-H), 7.12 
(d, J = 1.7 Hz, 1H, C4-H), 7.11–7.05 (m, 2H, 2 × ArC-H), 5.89 (d, J = 16.2 Hz, 1H, CH2N), 
5.37–5.22 (m, 1H, C10bIII-H), 4.97–4.86 (m, 2H, CH2N + C10bII-H), 3.03 (d, J = 5.3 Hz, 1H, 
CH2O), 2.76 (ddt, J = 13.9, 6.1, 1.3 Hz, 1H, C10bI-H2), 2.59 (ddt, J = 13.9, 6.1, 1.3 Hz, 1H, 
C10bI-H2), 2.52 (d, J = 5.3 Hz, 1H, CH2O), 1.50 (d, J = 6.0 Hz, 3H, CH3); 13C NMR (101 MHz, 
CDCl3) δ 172.6 (C5a), 151.0 (C6a), 142.0 (C4a), 137.2 (C10a), 136.1 (ArC), 130.8 (C10bIII), 
129.1 (ArCH), 129.0 (ArCH), 128.4 (ArC), 127.7 (ArCH), 126.9 (ArCH), 126.5 (ArCH), 125.2 
(ArCH), 123.3 (ArC), 123.1 (ArC), 122.9 (C10bII), 122.1 (C11a), 121.5 (ArCH), 118.4 (ArCH), 
59.5 (C11), 56.4 (C10b), 53.2 (CH2O), 50.0 (CH2N), 37.1 (C10bI), 17.8 (C10bIV); HR MS 
[APCI+]: m/z calcd. for C27H2279Br35Cl2N2O 539.0287, found 539.0275 [M+H]+. 
3.3.13. (10bR,11R)-5-Benzyl-3-bromo-10b-((E)-but-2-en-1-yl)-7,9-dichloro-10b,11-dihy-
dro-5H-indolo[2,3-b]quinolin-11-yl)methanol 32 
To a solution of 31 (90 mg, 0.167 mmol) in THF (3 mL) at -78 °C was added sodium 
cyanoborohydride (26 mg, 0.416 mmol) and boron trifluoride diethyl etherate (82μL, 0.666 
mmol). The mixture was slowly allowed to warm to room temperature over a period of 6 
h before a saturated solution of NaHCO3 (aq.) (6 mL) was added. The mixture was ex-
tracted with DCM (3 × 10 mL) before the combined organic extracts were dried (MgSO4), 
filtered and concentrated to give the crude product. The crude reaction mixture was pu-
rified by column chromatography (20–30 % EtOAc/hexanes) to give 32 as a white solid (45 
mg, 50%). m.p. 85–86 °C, I.R. (KBr) νmax 3419 (OH), 2931, 1545, 1486, 1422, 1206 cm-1; 1H 
NMR (300 MHz, CDCl3) δ 7.54 (dd, J = 8.3, 1.0 Hz, 1H, C2-H), 7.38–7.24 (m, 6H, 6 × ArC-
H), 7.23–7.16 (m, 2H, 2 × ArC-H), 7.10 (d, J = 1.9 Hz, 1H, ArC-H), 5.75 (d, J = 16.2 Hz, 1H, 
CH2N), 5.19 (dq, J = 13.0, 6.5 Hz, 1H, CH=CHCH3), 4.80 (d, J = 16.2 Hz, 1H, CH2N), 4.72–
4.58 (m, 1H, CH=CHCH2), 4.53 (dd, J = 11.2, 2.4 Hz, 1H, CH2OH), 4.39–4.26 (m, 1H, 
CH2OH), 3.00 (d, J = 6.2 Hz, 1H, C11-H), 2.42–2.26 (m, 2H, CH2), 2.14 (br., s, 1H, OH), 1.40 
(d, J = 6.5 Hz, 3H, CH3); 13C NMR (75 MHz, CDCl3) δ 174.4 (C5a), 151.9 (C6a), 142.3 (C4a), 
140.1 (C10a), 136.7 (ArC), 130.6 (C10bIII), 129.2 (2 × overlapping ArCH), 129.1 (C1), 128.0 
(ArCH), 127.5 (ArCH), 126.9 (C2), 125.0 (ArC), 124.5 (C11a), 123.8 (C10bII), 123.1 (ArC), 
122.9 (ArCH), 122.1 (C3), 119.1 (C4), 61.7 (CH2OH), 56.2 (C10b), 50.8 (CH2N), 44.0 (C11), 
33.9 (C10bI), 18.2 (C10bIV); HR MS [ES+]: m/z calcd. for C27H2379Br35Cl37ClN2ONa 565.0239, 
found 565.0220 [M+Na]+. 
3.3.14. (10bR,11R)-11-Allyl-5-benzyl-3-bromo-7,9-dichloro-10b-(2-hydroxyethyl)-10b,11-
dihydro-5H-indolo[2,3-b]quinolin-11-ol 40 
For details of the synthesis and analysis of the diastereomeric mixtures 37a/37b, 
38a/38b and 39a/39b see SI. To a solution of 39a/39b (230 mg, 0.413 mmol) in MeOH (10 
mL) was added NaBH4 (31 mg, 0.826 mmol) and the mixture was stirred at room temper-
ature for 1 h. A saturated solution of NH4Cl (aq.) (10 mL) was added and the organic 
solvent was removed under reduced pressure before the mixture was extracted with DCM 
(3 × 10 mL). The combined organic extracts were dried (MgSO4), filtered and concentrated 
in vacuo. The crude product was purified by column chromatography (15-25% 
EtOAc/hexanes) to give 40 as a white solid (220 mg, 95%). m.p. = 151–153 °C; I.R. (KBr) 
νmax 3163, 2931, 1545, 1481, 1418, 1206, 847, 729 cm−1; 1H NMR (500 MHz, CDCl3) δ 7.40–
7.31 (m, 6H, C8-H, C10-H, 4 × ArC-H), 7.30–7.25 (m, 2H, C1-H, ArC-H), 7.19 (dd, J = 8.1, 
1.7 Hz, 1H, C2-H), 7.13 (d, J = 1.7 Hz, 1H, C4-H), 5.56 (d, J = 16.1 Hz, 1H, CH2N), 5.38 (ddt, 
J = 17.3, 10.0, 7.3 Hz, 1H, C11II-H), 5.22 (d, J = 16.0 Hz, 1H, CH2N), 4.98–4.92 (m, 1H, C11III-
H2), 4.73 (dt, J = 17.0, 1.6 Hz, 1H, C11III-H2), 3.60 (ddd, J = 12.0, 8.7, 3.6 Hz, 1H, C10bII-H2), 
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3.52–3.45 (m, 1H, C10bII-H2), 2.41–2.32 (m, 1H, C10bI-H2), 2.12 (d, J = 7.0 Hz, 2H, C11I-H2), 
1.78–1.69 (m, 1H, C10bI-H2); 13C NMR (126 MHz, CDCl3) δ 175.4 (C5a), 150.9 (C6a), 138.9 
(C4a), 137.9 (C10a), 135.8 (ArC), 131.6 (C11II), 129.2 (C8), 128.9 (2 x overlapping carbons 
ArCH, C11a), 128.4 (ArCCl), 128.2 (C1 or ArCH), 127.9 (C1 or ArCH), 127.3 (ArCH), 126.4 
(C2), 122.9 (ArCCl), 122.7 (C10), 122.3 (C3), 120.0 (C11III), 118.6 (C4), 75.3 (C11), 61.3 (C10b), 
58.6 (C10bII), 49.4 (CH2N), 40.6 (C11I), 35.0 (C10bI). HR MS [ES+]: m/z calcd. for 
C27H2479Br35Cl2N2O2 557.0393, found 557.0392 [M+H]+. 
3.3.15. (3aR,13bR)-13b-Allyl-9-benzyl-11-bromo-5,7-dichloro-2,3,9,13b-
tetrahydrofuro[3,2-c]indolo [2,3-b]quinoline 41 
To a solution of 40 (50 mg, 0.090 mmol) in DCM (2 mL) was added p-toluenesulfonyl 
chloride (26 mg, 0.134 mmol) and triethylamine (124 μL, 0.896 mmol) and the mixture was 
stirred at room temperature for 1 h. The mixture was then heated to reflux for a further 5 
h before cooling to room temperature and addition of a saturated solution of NH4Cl (aq.) 
(5 mL). The mixture was extracted with DCM (3 × 5 mL) and the combined organic extracts 
were dried (MgSO4), filtered and concentrated in vacuo. The crude product was purified 
by column chromatography (5–15% EtOAc/hexanes) to give 41 as a white solid (40 mg, 
83%). Recrystallization of 41 by slow evaporation from ethyl acetate gave crystals of suit-
able quality for X-ray crystallographic analysis. m.p. = 177–179 °C; I.R. (KBr) νmax 2926, 
1548, 1484, 1425, 1204, 1071, 1044, 850 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.29–7.15 (m, 7H, 
C6-H, C13-H, 5 × ArC-H), 7.14 (d, J = 2.0 Hz, 1H, C4-H), 7.10 (dd, J = 8.2, 1.8 Hz, 1H, C12-
H), 7.00 (d, J = 1.8 Hz, 1H, C10-H), 5.62 (d, J = 16.1 Hz, 1H, CH2N), 5.06–4.95 (m, 2H, CH2N, 
C15-H), 4.67–4.60 (m, 1H, C16-H2), 4.39 (dq, J = 16.9, 1.3 Hz, 1H, C16-H2), 4.12 (q, J = 8.3 
Hz, 1H, C2-H2), 3.74 (ddd, J = 10.1, 8.6, 3.4 Hz, 1H, C2-H2), 2.49 (ddd, J = 12.6, 10.1, 8.2 Hz, 
1H, C3-H2), 2.38–2.35 (m, 2H, 14-H2), 2.03 (ddd, J = 12.2, 8.2, 3.4 Hz, 1H, C3-H2); 13C NMR 
(126 MHz, CDCl3) δ 171.6 (C8a), 149.2 (C7a), 139.2 (C3b), 139.0 (C9a), 134.9 (ArC), 128.9 
(C15), 127.9 (C6), 127.9 (ArCH), 127.7 (C13 or ArCH), 127.2 (ArCCl), 126.7 (C13 or ArCH), 
126.1 (ArCH), 125.5 (C12), 124.8 (C13a), 122.3 (ArCCl), 121.8 (C11), 120.1 (C4), 119.2 (C16), 
117.2 (C10), 85.0 (C13b), 63.3 (C2), 59.5 (C3a), 48.3 (CH2N), 40.5 (C14), 36.8 (C3); HR MS 
[ES+]: m/z calcd. for C27H2279Br35Cl2N2O 539.0287, found 539.0284 [M+H]+. 
3.3.16. (R)-2-(11,11-Diallyl-5-benzyl-3-bromo-7,9-dichloro-10b,11-dihydro-5H-indolo[2,3-
b]quinolin-10b-yl)ethanol 35 
To a solution of 41 (40 mg, 0.074 mmol) in DCM (1.5 mL) at −78 °C was added allyltri-
methylsilane (42 mg, 0.370 mmol) and TiCl4 (70 mg, 0.370 mmol) and the mixture was 
stirred at −78 °C for 4.5 h. Methanol (0.5 mL) was added and the mixture was stirred for 
an additional 10 min before the cold bath was removed and a saturated solution of NH4Cl 
(aq.) (5 mL) was added. The mixture was extracted with DCM (3 × 5 mL) and the combined 
organic extracts were dried (MgSO4), filtered and concentrated in vacuo. The crude prod-
uct was purified by column chromatography (15–30% EtOAc/hexanes) to give 35 as a pale 
yellow solid (34 mg, 79%). m.p. = 73–75 °C; I.R. (KBr) νmax 3389, 3074, 2921, 1607, 1548, 
1486, 1422, 1206, 909, 847, 798, 729, 702 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.47–7.39 (m, 
2H, 2 × ArC-H), 7.36–7.27 (m, 4H, C8-H, 3 x ArC-H), 7.23 (d, J = 1.9 Hz, 1H, C4-H), 7.19 (d, 
J = 1.9 Hz, 1H, C10-H), 7.15 (dd, J = 8.3, 1.9 Hz, 1H, C2-H), 7.03 (d, J = 8.3 Hz, 1H, C1-H), 
6.09 (ddt, J = 17.1, 9.6, 4.9 Hz, 1H, C11IIa-H), 5.44 (d, J = 15.9 Hz, 1H, CH2N), 5.38 (d, J = 17.1 
Hz, 1H, C11IIIa-H2), 5.28 (d, J = 15.9 Hz, 1H, CH2N), 5.17 (d, J = 10.2 Hz, 1H, C11IIIa-H2), 5.14–
5.03 (m, 1H, C11IIb-H), 4.82 (d, J = 10.0 Hz, 1H, C11IIIb-H2), 4.62 (d, J = 16.2 Hz, 1H, C11IIIb-
H2), 3.17–3.05 (m, 2H, C10bII-H2, C11Ia-H2), 2.95 (ddd, J = 10.6, 8.5, 5.3 Hz, 1H, C10bII-H2), 
2.75 (dd, J = 16.9, 9.2 Hz, 1H, C11Ia-H2), 2.34 (ddd, J = 13.4, 8.2, 5.3 Hz, 1H, C10bI-H2), 2.14–
2.03 (m, 2H, C10bI-H2, C11Ib-H2), 1.80–1.72 (m, 1H, C11Ib-H2); 13C NMR (101 MHz, CDCl3) 
δ 173.9 (C5a), 151.6 (C6a), 140.6 (C4a), 138.9 (C10a), 135.9 (ArCH), 135.8 (C11IIa), 132.6 
(C11IIb), 129.5 (C1), 129.1 (C8), 128.8 (ArCH), 128.1 (ArCCl), 127.7 (ArCH), 126.5 (C11a), 
125.9 (C2), 122.8 (ArCCl), 122.2 (C10), 121.6 (C3), 119.5 (C4), 119.2 (C11IIIb), 117.1 (C11IIIa), 
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60.5 (C10b), 58.7 (C10bII), 49.7 (CH2N), 45.9 (C11), 39.9 (C11Ib), 37.3 (C11Ia), 35.6 (C10bI); HR 
MS [ES+]: m/z calcd. for C30H2879Br35Cl2N2O 581.0757, found 581.0756 [M+H]+. 
3.3.17. 3a-(4-Allyl-1-benzyl-7-bromo-2-(iodomethyl)-1,2,3,4-tetrahydroquinolin-4-yl)-5,7-
dichloro-3,3a-dihydro-2H-furo[2,3-b]indole 45 
To a solution of 35 (18 mg, 0.031 mmol) in base-washed CDCl3 (1 mL) was added NIS 
(22 mg, 0.098 mmol) and the mixture was stirred at room temperature for 3 h. A saturated 
solution of Na2S2O3 (aq.) (2 mL) was added and the mixture was stirred for a further 10 
min before being extracted with DCM (3 × 2 mL). The combined organic extracts were 
dried (MgSO4), filtered and concentrated in vacuo. The crude product was purified by 
column chromatography (Et3N washed silica, 5–15% EtOAc/hexanes), giving 45 as a white 
solid (11 mg, 50%). I.R. (KBr) νmax 3320, 3074, 2921, 1607, 1548, 1486, 1420, 1255, 1206, 911, 
847, 798, 729 cm−1; 1H NMR (500 MHz, CDCl3) δ 7.40 (d, J = 2.0 Hz, 1H, C6-H), 7.38–7.27 
(m, 6H, C4-H, 5 × ArC-H), 7.19 (d, J = 8.3 Hz, 1H, C5′-H), 6.93 (dd, J = 8.3, 2.0 Hz, 1H, C6′-
H), 6.82 (d, J = 1.9 Hz, 1H, C8′-H), 5.70 (dddd, J = 17.8, 10.1, 7.9, 5.2 Hz, 1H, C4′II-H), 5.28–
5.17 (m, 2H, C4′III-H2), 4.64 (d, J = 17.9 Hz, 1H, CH2N), 4.46 (d, J = 17.8 Hz, 1H, CH2N), 4.31 
(t, J = 9.1 Hz, 1H, C2-H2), 3.51–3.42 (m, 1H, C2′-H), 3.26 (dd, J = 14.4, 5.2 Hz, 1H, C4′I-H2), 
3.07 (ddd, J = 10.0, 8.5, 6.3 Hz, 1H, C2-H2), 3.01 (dd, J = 9.7, 2.7 Hz, 1H, CH2I), 2.54 (q, J = 
7.2 Hz, 3H, 1 × C3-H2, 1 x C4′I-H2, 1 x CH2I), 2.09 (dt, J = 13.5, 10.0 Hz, 1H, C3-H2), 1.58 (dd, 
J = 8.9, 6.7 Hz, 2H, C3′-H2); 13C NMR (126 MHz, CDCl3) δ 193.6 (C8a), 153.8 (C7a), 149.4 
(C8a’), 140.3 (C3b), 139.0 (ArC), 132.2 (C4′II), 129.5 (C6), 129.1 (C5′), 128.7 (ArCH), 128.4 
(ArCCl), 127.2 (ArCH), 126.5 (ArCH), 124.3 (ArCCl), 123.6 (C4), 123.5 (C7′), 120.9 (C4a’), 
120.5 (C4′III), 120.5 (C6′), 118.3 (C8′), 79.9 (C2), 64.9 (C3a), 57.7 (CH2N), 56.8 (C2′), 45.0 (C4′), 
38.5 (C4′I), 37.8 (C3′), 27.5 (C3), 13.3 (CH2I); HR MS [ES+]: m/z calcd. for 
C30H2679Br35Cl2IN2ONa 728.9548, found 728.9554 [M+H]+. 
4. Conclusions 
The natural product perophoramidine (1) continues to challenge synthetic organic 
chemists. This report describes how the required presence of the two chlorines and one 
bromine in 1 forced us into a change in synthetic approach compared to our previous 
reports on dehaloperophoramidine (2). The optimization of an NCS-mediated intramo-
lecular C–N bond-forming reaction at the indole 2-position was achieved and led to a 
suitably halogen-substituted indoloquinoline core structure. Two attempts to progress 
further towards the structure of perophoramidine (1) are also described. In one of these 
approaches, the presence of the halogens blocked a previously observed undesired reac-
tion pathway. However, an alternative reaction pathway occurred, leading to a major re-
arrangement of the core structure of the molecule and delivering an interesting furo[2,3-
b]indole-containing structure. Throughout this work, small-molecule X-ray crystallo-
graphic analysis has proved essential. 
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